drugset / Trial / NCT01784614

A Study of LY2624803 in Japanese Participants With Transient Insomnia

NCT01784614

Phase 1 Completed 24 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blind

Summary

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods. Participants will receive a single dose of LY2624803 or placebo in each treatment period.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2624803 Small molecule 0.1 mg Oral
Subject LY2624803 Small molecule 1 mg Oral
Subject LY2624803 Small molecule 3 mg Oral
Subject LY2624803 Small molecule 6 mg Oral